🇺🇸 FDA
Pipeline program

Benralizumab

D3251C00014

Phase 3 mab completed

Quick answer

Benralizumab for Chronic Obstructive Pulmonary Disease is a Phase 3 program (mab) at AstraZeneca with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca
Indication
Chronic Obstructive Pulmonary Disease
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials